Hyloris Pharmaceuticals (LTS:0AB6) Total Long-Term Assets: €13.40 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0AB6 Hyloris Pharmaceuticals SA LTS:0AB6
64 GF Score
Price €4.70
GF Value €9.65
! 3 Warning Signs
View Full Analysis

What is Hyloris Pharmaceuticals Total Long-Term Assets?

Hyloris Pharmaceuticals LTS:0AB6 64 Total Long-Term Assets is €13.40 Mil as of Dec. 2025. GuruFocus rates LTS:0AB6 with a GF Score™ of 64/100 and a GF Value™ of €9.65. The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Hyloris Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Dec. 2025 was €13.40 Mil.

Hyloris Pharmaceuticals Total Long-Term Assets Related Terms

Hyloris Pharmaceuticals Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Hyloris Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hyloris Pharmaceuticals Total Long-Term Assets Chart

Hyloris Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.49 10.93 12.37 11.63 13.40

Hyloris Pharmaceuticals Semi-Annual Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.37 12.67 11.63 12.87 13.40
LTS:0AB6
64GF Score
Hyloris Pharmaceuticals SA LTS:0AB6
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hyloris Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €13.40 Mil mean?
Hyloris Pharmaceuticals (LTS:0AB6) has a Total Long-Term Assets of €13.40 Mil as of Dec. 2025. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Hyloris Pharmaceuticals and its competitors.
Is Hyloris Pharmaceuticals' Total Long-Term Assets too high?
Hyloris Pharmaceuticals' current Total Long-Term Assets is €13.40 Mil. Overall, Hyloris Pharmaceuticals has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' Total Long-Term Assets compare to VRTX and REGN?
Hyloris Pharmaceuticals' Total Long-Term Assets of €13.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Hyloris Pharmaceuticals and its competitors. Hyloris Pharmaceuticals's current Total Long-Term Assets is €13.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Hyloris Pharmaceuticals (LTS:0AB6) has a current Total Long-Term Assets of €13.40 Mil. The stock's GF Value™ is €9.65, compared to a current price of €4.70 — trading 51.3% below its estimated fair value. The current Total Long-Term Assets is €13.40 Mil. Hyloris Pharmaceuticals' overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current Total Long-Term Assets is €13.40 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?

Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued. The current stock price of €4.70 is trading 51.3% below its estimated GF Value™ of €9.65.

Key valuation signals for LTS:0AB6:

  • Total Long-Term Assets: €13.40 Mil
  • GF Value™: €9.65 vs. price of €4.70 (51.3% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hyloris Pharmaceuticals Business Description

Other Exchanges 52U:GermanyHYL:Belgium
Address Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
64GF Score

Get the complete analysis for LTS:0AB6

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.70
Price
€9.65
GF Value